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Summary
Background Worldwide, both the incidence and death rates of pancreatic cancer are increasing. Evaluation of 
pancreatic cancer burden and its global, regional, and national patterns is crucial to policy making and better resource 
allocation for controlling pancreatic cancer risk factors, developing early detection methods, and providing faster and 
more effective treatments.
Methods Vital registration, vital registration sample, and cancer registry data were used to generate mortality, 
incidence, and disability-adjusted life-years (DALYs) estimates. We used the comparative risk assessment framework 
to estimate the proportion of deaths attributable to risk factors for pancreatic cancer: smoking, high fasting plasma 
glucose, and high body-mass index. All of the estimates were reported as counts and age-standardised rates per 
100 000 person-years. 95% uncertainty intervals (UIs) were reported for all estimates.
Findings In 2017, there were 448 000 (95% UI 439 000–456 000) incident cases of pancreatic cancer globally, of which 
232 000 (210 000–221 000; 51·9%) were in males. The age-standardised incidence rate was 5·0 (4·9–5·1) per 
100 000 person-years in 1990 and increased to 5·7 (5·6–5·8) per 100 000 person-years in 2017. There was a 2·3 times 
increase in number of deaths for both sexes from 196 000 (193 000–200 000) in 1990 to 441 000 (433 000–449 000) in 
2017. There was a 2·1 times increase in DALYs due to pancreatic cancer, increasing from 4·4 million (4·3–4·5) in 
1990 to 9·1 million (8·9–9·3) in 2017. The age-standardised death rate of pancreatic cancer was highest in the high-
income super-region across all years from 1990 to 2017. In 2017, the highest age-standardised death rates were 
observed in Greenland (17·4 [15·8–19·0] per 100 000 person-years) and Uruguay (12·1 [10·9–13·5] per 100 000 person-
years). These countries also had the highest age-standardised death rates in 1990. Bangladesh (1·9 [1·5–2·3] per 
100 000 person-years) had the lowest rate in 2017, and São Tomé and Príncipe (1·3 [1·1–1·5] per 100 000 person-
years) had the lowest rate in 1990. The numbers of incident cases and deaths peaked at the ages of 65–69 years for 
males and at 75–79 years for females. Age-standardised pancreatic cancer deaths worldwide were primarily 
attributable to smoking (21·1% [18·8–23·7]), high fasting plasma glucose (8·9% [2·1–19·4]), and high body-mass 
index (6·2% [2·5–11·4]) in 2017.
Interpretation Globally, the number of deaths, incident cases, and DALYs caused by pancreatic cancer has more than 
doubled from 1990 to 2017. The increase in incidence of pancreatic cancer is likely to continue as the population ages. 
Prevention strategies should focus on modifiable risk factors. Development of screening programmes for early 
detection and more effective treatment strategies for pancreatic cancer are needed.
Funding Bill & Melinda Gates Foundation.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Cancer incidence and mortality are rapidly increasing 
worldwide.1,2 This increase is thought to be due to 
population growth and ageing, as well as changes in the 
prevalence of the main risk factors for cancer, several of 
which are associated with socioeconomic development.1,2
Pancreatic cancer remains one of the cancers with the 
poorest prognosis, with an overall 5-year survival rate of 
about 5%, without much difference between high-
income countries and low-income and middle-income 
countries.3 On the basis of the results of the previous 
iteration of the Global Burden of Diseases, Injuries, and 
Risk Factors Study (GBD), pancreatic cancer ranked 
eighth among cancers in mortality and 14th in incidence 
in 2016.1 Pancreatic cancer incidence and mortality vary 
considerably in the world.1 The highest incidence and 
mortality rates of pancreatic cancer are found in high-
income countries.2 Although the causes of pancreatic 
cancer are still insufficiently understood, certain risk 
factors have been identified, such as smoking, obesity, 
and diabetes.4 These risk factors probably explain some 
of the national variation.
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Data about incidence and trends of pancreatic cancer 
and its risk factors are scarce, specifically in nuanced time 
and location dimensions. GBD is the first comprehensive 
and systematic effort to report the incidence of and 
mortality and disability caused by pancreatic cancer and 
its risk factors, using an extensive set of data sources and 
novel statistical methods in seven super-regions, 
21 regions, and 195 countries and territories, for both 
sexes and 20 age groups, from 1990 to 2017. To our 
knowledge, this study is the first to investigate the 
association between development status (measured by 
the Socio-demographic Index [SDI]) and pancreatic 
cancer incidence and mortality at the national level.
Methods
Overview
This study is part of GBD. In the latest iteration, 
GBD 2017, 359 diseases and injuries, 282 causes of death, 
and 84 risk factors were estimated. The rationale, 
methods, and summary results of GBD 2017 have been 
published previously.5–8 Rates and numbers of deaths, 
incident cases, years of life lost (YLLs) as a result of 
premature death, years lived with disability (YLDs), and 
disability-adjusted life-years (DALYs) were reported for 
both males and females, 17 age groups, and 195 countries 
and territories.
The rates were age-standardised according to the world 
population estimated by the GBD study.9 95% uncertainty 
intervals (UIs) were reported for all estimates, including 
all sources of uncertainty arising from measurement 
error, systematic biases, and modelling. This study is 
compliant with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER).
Data sources
We considered all cancers coded as C25–C25.9 in the 
10th revision of the International Classification of 
Diseases to be pancreatic cancer and mapped them to the 
GBD cause list.5,7 For this study, we used GBD 2017 vital 
registration and sample vital registration (19 321 site-
years of data) and cancer registry (4472 site-years) data.7 
Vital registration systems include vital event data from all 
residents in a population, including causes of death. 
Sample vital registration systems include nationally 
representative data from which birth rates, death rates, 
and causes of death can be estimated. Cancer registries 
include data on all cancer patients in a defined 
population, typically from a particular location. Detailed 
information on data sources used in this study can be 
found on the GBD 2017 Data Input Sources Tool website.
Mortality estimates
Data coverage and quality were higher for mortality 
data than for other measures of pancreatic cancer 
burden. The cancer registry mortality estimates that 
were uploaded into the causes of death database were 
derived from cancer registry incidence data that had 
been transformed to mortality estimates through the 
use of mortality-to-incidence ratios (MIRs). We 
modelled MIRs using the locations that had both 
incidence and mortality data for the same year. The 
initial MIR model used a linear-step mixed-effects 
Research in context
Evidence before this study
Pancreatic cancer was estimated as the seventh leading cause of 
cancer death in both sexes worldwide in 2018, on the basis of the 
Global Cancer Incidence, Mortality and Prevalence 
2018 estimates, from 185 countries, using subregional rather 
than national data. Because of the poor prognosis of pancreatic 
cancer, there were almost as many deaths (n=432 000) as there 
were cases (n=459 000). The rates reported were three times to 
four times higher in higher Human Development Index countries, 
with incidence rates being highest in Europe, North America, 
Australia, and New Zealand, and lowest in south central Asia. To 
our knowledge, there were no estimates of temporal patterns, 
trends, age patterns, years of life lost, disability-adjusted 
life-years, and associated risk factors of pancreatic cancer at 
national, regional, global, and socioeconomic levels before the 
Global Burden of Disease Study (GBD).
Added value of this study
We present estimates of the global burden of pancreatic cancer 
based on results from GBD 2017, which are reported by sex and 
age groups for 195 countries and territories from 1990 to 2017. 
We also investigated the association of socioeconomic 
development status with incidence and mortality caused by 
pancreatic cancer at the national level. We believe that this 
analysis provides the most comprehensive picture of the burden 
of pancreatic cancer to date. Examining trends of pancreatic 
cancer from 1990 to 2017 and comparisons across populations 
offers important information about the changing burden of 
pancreatic cancer to aid in the allocation of necessary resources 
at local levels to help control this lethal cancer.
Implications of all the available evidence
The incidence and mortality rates of pancreatic cancer 
increased in almost all countries and territories from 
1990 to 2017. With population growth and increases in 
longevity, clinicians and policy makers might expect a further 
substantial rise in the absolute number of pancreatic cancer 
cases, particularly in low-income and middle-income nations. 
Existing data gaps are a major challenge for policy making at 
the regional and national scale. To our knowledge, this study is 
the first effort to provide comprehensive worldwide estimates 
of the burden, epidemiological features, and risk factors of 
pancreatic cancer. Future studies should explore the predictors 
of these epidemiological trends to help policy makers 
implement cost-effective interventions for prevention, 
early detection, and control of pancreatic cancer.
For the GBD 2017 Data Input 
Sources Tool see http://ghdx. 
healthdata.org/gbd-2017/data-
input-sources
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model with logit link functions. The resulting estimates 
were then smoothed over place and time, and adjusted 
using spatiotemporal Gaussian process regression 
(see appendix of reference 10).10 The vital registration 
mortality, as well as the cancer registry mortality 
estimates computed from MIRs, were used as inputs 
for a Cause of Death Ensemble model.7,11
Non-fatal estimates
Pancreatic cancer incidence was computed by dividing the 
final mortality estimates by the MIR. Four sequelae were 
defined for pancreatic cancer—diagnosis and primary 
therapy phase, controlled phase, metastatic phase, and 
terminal phase.1 The diagnosis and primary therapy phase 
was defined as 4·1 months, the disseminated and 
metastatic phase as 2·54 months, and terminal phase as 
1·0 month.12,13 The remaining time was assigned to the 
controlled phase. Following this process, to estimate the 
sequelae-specific YLDs, we multiplied each sequela-
specific prevalence rate by a sequela-specific disability 
weight. Each of the four sequelae had defined disability 
weights that ranged from 0·049 to 0·540 (appendix p 8). 
DALYs were calculated as the sum of YLDs and YLLs.
SDI
We used the SDI to determine the relationship between 
pancreatic cancer incidence and mortality rates with 
development status at national and regional levels. The 
SDI ranges from 0 (worst) to 1 (best) and is composed of 
the total fertility rate among women under the age of 
25 years, mean education for individuals aged 15 years 
and older, and lag-distributed income per capita.5–7 
Components were extracted using principal components 
analysis. Each component was given equal weight, and 
the final SDI score was computed as the geometric mean 
of each of the components.
Risk factors 
We used the comparative risk assessment framework to 
estimate the proportion of deaths and DALYs attributable 
to three recognised risk factors for pancreatic cancer: 
smoking, high fasting plasma glucose, and high body-
mass index (BMI). We used the counterfactual scenario 
of theoretical minimum risk exposure level to model the 
population attributable fraction. The definitions of the 
framework have already been published.8
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and the final responsibility for 
the decision to submit for publication.
Results
The number of incident cases of pancreatic cancer in 
both sexes increased 2·3 times from 195 000 (95% UI 
192 000–199 000) incident cases in 1990 to 448 000 
(439 000–456 000) cases in 2017 globally (appendix p 19). 
In 2017, 51·9% (232 000 [210 000–221 000]) of the total 
incident cases occurred in males, compared with 52·1% 
(102 000 [99 000–106 000]) in 1990.
The global age-standardised incidence rate was 
5·0 (95% UI 4·9–5·1) per 100 000 person-years in 1990, 
which increased to 5·7 (5·6–5·8) per 100 000 person-years 
in 2017 (appendix p 19). Globally, there were 9·1 million 
(8·9–9·3) DALYs due to pancreatic cancer in 2017. This 
was a 2·1 times increase from 4·4 million (4·3–4·5) 
DALYs in 1990 (appendix p 27). 99% of all DALYs in all 
years were due to YLLs (appendix p 7).
In 2017, pancreatic cancer caused 441 000 (95% UI 
433 000–449 000) deaths globally, including 226 000 
(51·3%; 219 000–233 000) deaths among males and 
215 000 (48·7%; 211 000–220 000) deaths among females. 
There was a 2·3 times (125% [118–131]) increase in the 
number of deaths globally from 1990 to 2017, increasing 
from 196 000 (193 000–200 000) deaths for both sexes 
combined in 1990. The age-standardised death rate 
increased by 10·4% (7·0–13·0), from 5·1 (5·0–5·2) per 
100 000 person-years in 1990 to 5·6 (5·5–5·7) per 
100 000 person-years in 2017 (appendix p 11). The age-
standardised death rate in males was 5·7 (5·6–5·9) per 
100 000 person-years in 1990 and 6·3 (6·1–6·5) per 
100 000 person-years in 2017. The equivalent findings for 
females were 4·5 (4·5–4·6) per 100 000 person-years in 
1990 and 5·0 (4·9–5·1) per 100 000 person-years in 2017.
The age-standardised death rate was highest in the 
high-income super-region across all years from 
1990 to 2017: 8·1 (8·1–8·2) per 100 000 person-years in 
1990 and 8·6 (8·5–8·8) per 100 000 person-years in 2017 
(appendix p 2). Central Europe, eastern Europe, and 
central Asia ranked second at 6·8 (6·5–7·0) per 
100 000 person-years in 1990 and 7·6 (7·5–7·8) per 
100 000 person-years in 2017. South Asia had the lowest 
rates: 1·6 (1·4–1·8) per 100 000 person-years in 1990 and 
2·9 (2·7–3·0) per 100 000 person-years in 2017. The 
pattern of age-standardised incidence rates in super-
regions was similar to the pattern we observed for age-
standardised death rate (appendix p 2). The pattern of 
age-standardised incidence and death rates was also 
similar between sexes (data not shown).
Age-standardised incidence and death rates increased 
in all GBD regions from 1990 to 2017 (figure 1). High-
income North America and western Europe were among 
the top three regions for highest age-standardised rates 
of both incidence and deaths in 2017, with high-income 
Asia Pacific and central Europe also in the top three for 
highest age-standardised rate of incidence and death, 
respectively (figure 1). These regions all had smaller 
increases in age-standardised rates of incidence and 
deaths from 1990 to 2017 than many other regions 
(figure 1B, D; appendix pp 11–26). The lowest age-
standardised incidence and death rates in 2017 were 
observed in south Asia and eastern and central 
See Online for appendix
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sub-Saharan Africa (figure 1A, C). The Caribbean, 
Andean Latin America, and central Asia had the highest 
percentage change in both incidence and death rates 
from 1990 to 2017 (figure 1B, D). The age-standardised 
rates for both incidence and death were higher among 
males than females in almost all regions and all years 
from 1990 to 2017, with the exception of Andean Latin 
America and western sub-Saharan Africa (figure 1A, C).
Age-specific rates for both incidence and deaths 
increased with increasing age; this trend was similar 
between males and females (figure 2A, B). The number 
of both deaths and incident cases peaked at the ages of 
65–69 years in males, whereas the peak in females was 
observed at the ages of 75–79 years. Additionally, the 
numbers of deaths and incident cases were lower in 
females younger than 75 years than in males in the same 
age group, whereas the numbers were higher in females 
than in males in age groups of 75 years and older 
(figure 2A, B). Until the ages of 90–94 years, the incidence, 
death, and DALYs rates were higher in males than in 
females in the same age group (figure 2). The age pattern 
for number of DALYs showed a similar trend to number 
of deaths and incident cases for total counts, but the rates 
decreased in age groups older than 80 years. Similar to 
the number of incident cases and deaths, in 2017 the 
number of DALYs was much higher in males than in 
females in all age groups younger 75 years, after which 
female DALY numbers were higher (although with over-
lapping uncertainty in the age group  of 75–79 years).
In both 1990 and 2017, the highest age-standardised 
death rates were observed in Greenland: 19·7 (95% UI 
17·8–21·8) per 100 000 person-years in 1990 and 17·4 
(15·8–19·0) per 100 000 person-years in 2017 (figure 3A; 
appendix p 11). Yet the number of deaths due to pancreatic 
Figure 1: Levels and trends in age-standardised incidence and death rates of pancreatic cancer across 21 GBD regions by sex
(A) The age-standardised incidence rates of pancreatic cancer in 2017. (B) The percentage change in age-standardised incidence rate of pancreatic cancer from 1990 to 2017. (C) The age-standardised death 
rates of pancreatic cancer in 2017. (D) The percentage change in age-standardised death rate of pancreatic cancer from 1990 to 2017. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study.
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cancer in Greenland was among the lowest in the world 
(11·1 [10·2–12·1] in 2017). Uruguay was the next leading 
country for highest age-standardised death rates from 
pancreatic cancer, although it was substantially behind 
Greenland, with an age-standardised death rate of 12·1 
(10·9–13·5) per 100 000 person-years in 2017. Bangladesh 
(1·9 [1·5–2·3] per 100 000 person-years) had the lowest 
age-standardised rate in 2017, whereas São Tomé and 
Príncipe (1·3 [1·1–1·5] per 100 000 person-years) had the 
lowest rate in 1990. The incidence rates followed a very 
similar pattern: highest in Greenland in both 1990 and 
2017, lowest in São Tomé and Príncipe in 1990, and 
lowest in Bangladesh in 2017 (figure 3B). All estimates 
were similar between males and females (data not 
shown). Specific country and territory data for incidence, 
deaths, and DALYs can be found in the appendix 
(pp 11–34). 
The average annualised percentage change in both age-
standardised incidence and death rates was highest in 
Grenada (5·5%) and lowest in Bahrain (–1·2%) from 
1990 to 2017. For males, the percentage change in both 
age-standardised incidence and death rates was highest 
in Bermuda (6·0%) and lowest in Qatar (–1·5% for age-
standardised incidence rate and –1·6% for age-
standardised death rate). For females, the highest 
percentage change in both age-standardised incidence 
and death rates was in Grenada (5·4% for age-standardised 
incidence rate and 5·5% for age-standardised death rate) 
and the lowest in Bahrain (–1·2%). 
93 600 (95% UI 82 500–108 000) pancreatic cancer deaths, 
equivalent to 21·1% (18·8–23·7) of all age-standardised 
deaths from pancreatic cancer, were attributable to 
smoking for both sexes combined in 2017. The age-
standardised proportions of all pancreatic cancer deaths 
that were attributable to smoking in 2017 were 25·9% 
(22·2–29·6) for males and 16·1% (13·2–18·8) for females 
(figure 4A). 59 000 (63·1%; 50 000–68 000) of these deaths 
occurred in males and 33 500 (36·1%; 28 000–41 000) in 
females. In 1990, the proportion of pancreatic cancer age-
standardised deaths attributable to smoking was 26·6% 
(23·8–29·5) for both sexes combined.
Globally, in 2017, 8·9% (2·1–19·4) of pancreatic cancer 
age-standardised deaths were attributable to high fasting 
plasma glucose, including 9·3% (1·7–21·3) in males and 
8·6% (1·4–19·6) in females (figure 4A; appendix pp 8–9), 
compared with 7·7% (1·8–16·8) for both sexes combined 
in 1990. Likewise, 6·2% (2·5–11·4) of pancreatic cancer 
age-standardised deaths were attributable to high BMI, 
including 5·0% (0·0–12·1) in males and 7·4% (2·6–13·0) 
in females (figure 4A; appendix pp 8–9), compared with 
5·0% (1·9–9·6) for both sexes combined in 1990.
In 2017, the proportion of age-standardised deaths 
attributable to smoking for males was highest in eastern 
Europe (35·7% of all pancreatic cancer deaths) and east 
Asia (31·3%); for females it was highest in high-
income North America (29·3%) and southern Latin 
America (27·6%). The lowest age-standardised attributable 
proportion for smoking was observed in western sub-
Saharan Africa for both males (8·0%) and females (2·1%). 
In 2017, the highest proportion of age-standardised deaths 
attributable to high fasting plasma glucose was observed 
in Oceania in both males (16·0%) and females (17·3%), 
and the highest fraction attributable to high BMI was 
observed in high-income North America for both 
males (8·6%) and females (11·7%). Additionally, in 2017, 
the lowest proportion of age-standardised deaths 
Figure 2: Age-specific counts and rates of incident cases (A), deaths (B), and DALYs (C) of pancreatic cancer by 
sex, 2017
DALYs=disability-adjusted life-years.
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Figure 3: Age-standardised rates of incidence (A) and death (B) of pancreatic cancer across 195 countries and territories in both sexes, 2017
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attributable to high fasting plasma glucose was observed 
in east Asia in males (5·8%) and in tropical Latin America 
in females (6·1%). As for proportion of deaths attributable 
to high BMI, the lowest proportion in males was observed 
in eastern sub-Saharan Africa (2·1%), and in females the 
lowest proportion was observed in high-income Asia 
Pacific (3·5%; figure 4A).
Across age groups, the proportion of age-standardised 
deaths attributable to smoking was higher than 25% in 
males aged between 55 and 84 years and higher than 
16% in females in the same age group (figure 4B). The 
highest proportion attributable to high fasting plasma 
glucose in both sexes was observed in the 85–89 year 
age group. Although higher proportions of pancreatic 
cancer deaths attributable to high BMI were observed 
between the ages of 45 years and 79 years, the 
proportions were more similar between all age groups 
than for the leading risk factors, with attributable 
deaths starting to occur at the ages of 20–24 years 
(figure 4B).
From 1990 to 2017, the age-standardised rates of both 
deaths and incidence of pancreatic cancer increased, 
along with increases in SDI. That is, the lowest rates 
were observed in low SDI countries and higher rates 
were detected in countries with respectively higher SDI 
across all years from 1990 to 2017 (appendix p 3).
Figure 4: Fraction of pancreatic cancer age-standardised deaths attributable to smoking, high fasting plasma glucose, and high body-mass index by region (A) and fraction of pancreatic 
cancer age-specific deaths attributable to smoking, high fasting plasma glucose, and high body-mass index by age group (B) for males and females, 2017
13·8%
14·1%
9·5%
8·3%
16·0%
5·8%
10·1%
8·8%
10·8%
11·8%
7·7%
10·4%
9·9%
11·6%
11·2%
6·0%
8·0%
8·0%
10·9%
11·8%
8·0%
9·3%
13·2%
3·6%
5·4%
2·1%
14·1%
7·7%
9·1%
4·8%
8·6%
4·5%
10·7%
27·0%
19·7%
27·6%
13·3%
23·6%
7·2%
24·9%
26·7%
29·3%
14·3%
16·1%
17·7%
14·4%
12·1%
8·0%
19·0%
31·3%
27·7%
17·6%
24·8%
27·2%
35·7%
29·3%
22·2%
24·8%
17·9%
22·0%
13·7%
17·9%
25·6%
22·4%
28·1%
25·9%
12·5%
12·3%
8·2%
7·9%
17·3%
6·3%
11·1%
8·5%
11·0%
10·8%
8·0%
9·0%
9·2%
10·3%
9·6%
6·1%
7·5%
7·1%
9·2%
9·5%
6·5%
8·6%
11·5%
3·9%
4·2%
5·6%
6·4%
4·9%
4·4%
3·9%
10·9%
9·7%
11·2%
10·9%
9·1%
8·9%
9·7%
9·3%
8·7%
10·4%
7·8%
11·7%
3·5%
7·4%
4·9%
2·6%
2·1%
3·0%
4·1%
3·1%
2·6%
2·3%
6·7%
5·4%
6·5%
7·3%
6·1%
6·6%
6·1%
6·1%
5·6%
7·5%
6·3%
8·6%
2·9%
5·0%
5·3%
10·1%
15·3%
20·0%
23·7%
25·9%
28·3%
29·0%
28·4%
27·4%
25·6%
23·1%
18·8%
17·3%
2·8%
4·8%
6·8%
9·4%
12·5%
16·6%
17·3%
18·1%
17·9%
17·7%
16·4%
14·4%
12·6%
12·1%
1·8%
2·4%
3·1%
4·0%
4·9%
6·0%
7·3%
8·3%
9·1%
9·9%
10·5%
11·0%
11·3%
11·2%
10·6%
1·5%
2·0%
2·6%
3·3%
4·2%
5·2%
6·4%
7·5%
8·3%
9·0%
9·7%
10·2%
10·3%
10·0%
9·1%
2·8%
3·8%
4·4%
5·1%
5·3%
5·4%
5·7%
5·9%
5·6%
5·4%
5·0%
4·7%
4·0%
4·2%
4·4%
4·5%
3·8%
4·9%
5·9%
6·8%
7·1%
7·6%
7·9%
8·6%
8·4%
8·2%
7·7%
7·4%
6·2%
6·3%
6·5%
6·3%
20–24
25–29
30–34
35–39
40–44
45–49
50–54
55–59
60–64
Ag
e 
gr
ou
p 
(y
ea
rs
)
65–69
70–74
75–79
80–84
85–89
90–94
≥95
B
0 5 10 15 20 25 15 25 15 25 15 25 15 25 15 2530
Deaths attributable
to risk factors (%)
0 5 10 20 30
Deaths attributable
to risk factors (%)
0 5 10 20 30
Deaths attributable
to risk factors (%)
0 5 10 20 30
Deaths attributable
to risk factors (%)
0 5 10 20 30
Deaths attributable
to risk factors (%)
0 5 10 20 30
Southern sub-Saharan Africa
Central sub-Saharan Africa
Eastern sub-Saharan Africa
Western sub-Saharan Africa
Oceania
East Asia
Southeast Asia
South Asia
North Africa and Middle East
Central Asia
Eastern Europe
Central Europe
Caribbean
Southern Latin America
Central Latin America
Tropical Latin America
Andean Latin America
Australasia
Western Europe
High-income North America
High-income Asia Pacific
Global
A
0 5 10 15 20 25 30 0 5 10 15 20 25 30 0 5 10 15 20 25 30 0 5 10 15 20 25 30 0 5 10 15 20 25 30 0 5 10 15 20 25 30
Deaths attributable
to risk factors (%)
Smoking
Males Females
High fasting plasma glucose High body-mass index
Articles
8 www.thelancet.com/gastrohep   Published online October 21, 2019   https://doi.org/10.1016/S2468-1253(19)30347-4
Figure 5 demonstrates the trend in age-standardised 
death rates across SDI by region, from 1990 to 2017. 
Regions generally followed the trend of increasing death, 
incidence, and DALY rates along with increases in SDI 
(figure 5; appendix pp 4–5). Several regions, including 
Andean Latin America and southern sub-Saharan Africa, 
showed a decrease in age-standardised death rate late in 
the study period, but not down to 1990 levels. Among 
high-income regions, Australasia had a rising age-
standardised death rate but it was well below the expected 
levels in all years, while other high-income regions were 
either near or above the levels expected on the basis of 
SDI. Although south Asia, southeast Asia, and east Asia 
had rising age-standardised death rates, they were among 
the lowest in the world and were below the expected levels 
in all years from 1990 to 2017. Figure 6 demonstrates the 
association between age-standardised death rate and SDI 
across countries and territories in 2017. Similar to regional 
trends, there was a trend at the national level of increasing 
age-standardised death rates along with increases in SDI. 
As mentioned previously, the observed levels were much 
higher than expected in Greenland and Uruguay and 
much lower than expected in many countries, including 
Bangladesh, Kuwait, and Singapore based solely on SDI.
Discussion
Our results showed that there were approximately 
441 000 deaths due to pancreatic cancer worldwide in 2017. 
The incidence and death rates of pancreatic cancer for 
both sexes varied greatly across GBD regions. The 
2017 age-standardised death rates for pancreatic cancer 
were highest in Greenland and Uruguay. The lowest were 
observed in Bangladesh and São Tomé and Príncipe. 
Although there was not a clear explanation for such great 
differences in pancreatic cancer mortality in different 
regions of the world, this national variation could be 
attributed to exposure to known or suspected lifestyle and 
environmental risk factors related to pancreatic cancer as 
well as scarcity of efficient diagnostic tools in low-income 
and middle-income countries.14,15 The substantial increase 
in worldwide pancreatic cancer suggests that change in 
ageing populations, especially in low and middle SDI 
countries, and environmental and behavioural changes, 
more so than genetic factors, are related to its cause. 
Differences in pancreatic cancer death and incidence rates 
across countries could also reflect variation in quality of 
cancer registry data and tools for pancreatic cancer 
diagnosis.16,17
Since 1990, regional age-standardised death and 
incidence rates of pancreatic cancer generally increased 
with increasing SDI. During the past three decades, 
these rates were consistently higher in high SDI regions 
and lower in low SDI regions. Higher incidence of 
pancreatic cancer in high SDI countries could be due to 
the ageing population and to lifestyle choices that 
increase exposure to risk factors; some of the risk factors 
for pancreatic cancer are more prevalent in high SDI 
countries than in low ones.2,18
There was a 2·3 times increase in global number of 
incident cases and deaths of pancreatic cancer in both 
sexes from 1990 to 2017, reflecting both ageing and growth 
of the population, especially in low and middle SDI 
countries. The age-standardised death and incidence rates 
increased from 1990 to 2017 at the global level. This 
Figure 5: The trend in age-standardised death rates of pancreatic cancer across 21 GBD regions by SDI for both sexes combined, 1990–2017
For each region, points from left to right depict estimates from each year from 1990 to 2017. GBD=Global Burden of Diseases, Injuries, and Risk Factors Study. 
SDI=Socio-demographic Index.
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increase was probably related to an increase in the 
prevalence of obesity and diabetes, as reflected by the risk 
factors of high BMI and fasting plasma glucose, two of the 
known risk factors for pancreatic cancer.15,19,20 This increase 
occurred despite a mild-to-moderate reduction in smoking 
rates in high-income countries over the study period.21
The incidence and mortality of pancreatic cancer were 
somewhat higher in males than in females across age 
groups lower than 75 years in all years from 1990 to 2017; 
51·9% of pancreatic cancer deaths occurred in males and 
48·1% in females. This pattern is consistent with other 
worldwide studies.3,22 The reasons for lower incidence of 
pancreatic cancer in females are not completely 
understood. Females are either less prone to pancreatic 
cancer or have less exposure to smoking as the main 
environmental risk factor of pancreatic cancer.4 Smoking 
in males (25·0%) is five times more frequent than in 
females (5·4%) worldwide.21
High-income regions had the highest death and 
incidence rates of pancreatic cancer for both sexes 
combined in all years from 1990 to 2017. Similar to other 
comparable studies, we found that pancreatic cancer is 
mainly a disease of high-income countries, where overall 
rates are nearly three times higher than in middle-income 
and low-income countries, but age-standardised rates are 
increasing at similar rates among countries with different 
SDI levels.2,22 A forecasting study has predicted that 
pancreatic cancer will escalate from the fourth to the 
second leading cause of cancer deaths in the USA 
by 2030,23 and another study forecasted that 111 500 deaths 
from pancreatic cancer will occur in the European region 
by 2025, an almost 50% increase in the number of 
recorded deaths from pancreatic cancer in 2010.24,25
Pancreatic cancer is typically a disease of older people, 
since 90% of newly diagnosed patients are aged older 
than 55 years, with most in their seventh and eighth 
decades of life.3,22 Although pancreatic cancer rarely 
presents before the age of 45 years, the incidence rises 
sharply thereafter. As survival for chronic diseases 
improves, the number of older patients diagnosed with 
pancreatic cancer is increasing. Age is the most 
important risk factor in the development of pancreatic 
cancer. We found the number of both deaths and incident 
cases had a peak in the age group of 65–69 years in 
males, whereas the peak in females was observed in the 
age group of 75–79 years. Using a life table approach is 
necessary to assess differences in exposure and genetic 
susceptibility among males and females with pancreatic 
cancer. It has not been reported previously that females 
experience pancreatic cancer at older ages than males.
Pancreatic cancer remains one of the deadliest cancers, 
with a 5% 5-year survival rate.22 5-year survival rates from 
pancreatic cancer have changed little over the past 
decades. The current rate of 5% is only slightly improved 
from 3% in 1970.26 Pancreatic cancer is often diagnosed at 
advanced stages and responds poorly to chemotherapy, 
leading to low treatment success rates.22
The estimated population attributable fraction of 
pancreatic cancer deaths to tobacco smoking is 11–32%.27 
We found that the proportion of age-standardised deaths 
attributable to smoking decreased slightly from 1990 
(26·6% [95% UI 23·8–29·5]) to 2017 (21·1% [18·8–23·7]) 
in both sexes combined, but it was still higher than the 
proportion of age-standardised deaths attributable to high 
fasting plasma glucose (8·9% [2·1–19·6]) and high 
BMI (6·2% [2·5–11·4]) in 2017. Reductions in the 
proportion of pancreatic cancer cases attributable to 
smoking are similar worldwide reductions in smoking 
rates. Globally, the age-standardised prevalence of daily 
smoking decreased by 28·4% for males and 34·4% for 
Figure 6: The age-standardised death rates of pancreatic cancer across 195 countries and territories by SDI in both sexes, 2017
SDI=Socio-demographic Index.
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females between 1990 and 2015; however, four countries 
had significant annualised increases in smoking 
prevalence between 2005 and 2015 (Congo and Azerbaijan 
for males and Kuwait and Timor-Leste for females).21 On 
the basis of a 2012 study28 by the International Pancreatic 
Cancer Case-Control Consortium (PanC4; 6507 pancreatic 
cancer cases, 12 890 controls), former smokers, in 
comparison with never smokers, had an odds ratio (OR) 
of 1·2 (95% CI 1·0–1·3), and current smokers, in 
comparison with never smokers, had an OR of 
2·2 (1·7–2·8), for risk of pancreatic cancer, with a trend of 
significantly increasing risk of pancreatic cancer with 
increasing number of cigarettes among current smokers 
(OR 3·4 for ≥35 cigarettes per day, ptrend<0·0001). Risk 
increased in relation to duration of cigarette smoking up 
to 40 years of smoking (OR 2·4).28 No trend in risk was 
observed for age at starting cigarette smoking, whereas 
risk decreased with increasing time since cigarette 
cessation, with an OR of 0·98 after 20 years.28 We found 
that the highest proportion of pancreatic cancer deaths 
attributable to smoking for both sexes was observed in 
the 55–84 year age group, which is consistent with the 
findings from the PanC4.28 The International Agency for 
Research on Cancer confirmed that smoking is causally 
associated with pancreatic cancer.29
Type 2 diabetes has been linked with an excess risk of 
pancreatic cancer in several studies.30–32 We found that 
8·8% of pancreatic cancer deaths were attributable to 
high fasting plasma glucose in both sexes in 2017. 
By comparison, a population study in Italy estimated that 
9·7% of pancreatic cancer occurrence was attributable to 
diabetes.33 The US National Cancer Institute estimated 
that diabetes is associated with a 1·8 times increased risk 
of pancreatic cancer.34 From 1980 to 2014, in all countries, 
diabetes prevalence in adults either increased, especially 
in low and middle SDI locations, or at best remained 
unchanged; worldwide, the number of adults with 
diabetes has quadrupled,19 so it is expected that diabetes 
will have a greater contribution to pancreatic cancer 
occurrence in the future.
Large studies have indicated a positive association 
between increasing BMI and risk of pancreatic cancer.18,35 
A pooled study35 of seven prospective cohorts showed 
that compared with normal weight (BMI 18·5 to <25), 
the adjusted relative risk for pancreatic cancer was 
1·13 for overweight (BMI 25 to <30 kg/m²) and 1·19 for 
obesity class I (BMI 30 to <35 kg/m²). A pooled analysis 
from the Pancreatic Cancer Cohort Consortium18 showed 
that in males, the adjusted OR for pancreatic cancer for 
the highest versus lowest quartile of BMI was 1·33, and 
in females it was 1·34. The prevalence of obesity 
(BMI ≥30 kg/m²) is increasing at an alarming rate in 
many parts of the world. The number of obese people 
has risen globally from 105 million in 1975 to 641 million 
in 2014. Since 1975, the prevalence of obese males has 
more than tripled, and that of obese females has 
more than doubled.36 More than 2 billion people are 
overweight, and a third of them are obese. By 2025, 
global obesity prevalence is projected to reach 18% in 
males and surpass 21% in females; severe obesity is 
likely to surpass 6% in males and 9% in females.19 We 
found that 6·2% of pancreatic cancer in both sexes 
(5·0% in males, 7·4% in females) was attributable to 
obesity, which is inconsistent with estimated population 
attributable fractions (3–16%).27 Although obesity carries 
a modest risk for pancreatic cancer, its rapid increase 
makes it a serious risk factor for pancreatic cancer, 
especially in females, who are more commonly obese 
than males.
Future strategies should include comprehensive 
policies to control tobacco use and reduce the burden of 
obesity and diabetes across the world. Additionally, 
efforts must be made to identify other modifiable risk 
factors for pancreatic cancer, such as opium use in North 
Africa and the Middle East.37,38
This study has several limitations. Generally, as for 
estimation of all diseases and cancers in the GBD study, 
the major limitation of the current study is the lack of 
high-quality data in many regions and countries, 
particularly in low-income locations. Although we did a 
sensitive search to take advantage of all available data 
sources comprising cancer registries and vital registration 
systems, in many locations data were either sparse or 
entirely unavailable. For estimating pancreatic cancer 
burden in these locations, we had to base our estima- 
tions on covariates and spatiotemporal smoothing. 
Ascertainment bias, detection bias, and diagnostic 
inaccuracy were additional limitations in low-income 
locations. The reported high incidence and mortality of 
pancreatic cancer in high-income versus low-income 
locations might be partly related to availability of accurate 
diagnostic modalities for pancreatic cancer and richness 
of data in high-income regions. Additionally, all of the 
general limitations in estimating the burden attributable 
to risk factors through comparative risk assessment 
methods were challenging. Finally, because of lags in 
data availability, recent estimates of trends relied on 
covariates and past trends, leading to wider UIs.
Pancreatic cancer deaths and incidence more than 
doubled over the study period. Much of this increase was 
due to increases in population and longevity, but even 
after accounting for population changes, incidence and 
death rates increased from 1990 to 2017, probably due to 
changes in associated risk factors. Pancreatic cancer is an 
aggressive cancer, predicted to become the second 
leading cause of cancer deaths in some regions. It often 
presents in old age, at an advanced stage, and has a poor 
prognosis. Major risk factors associated with pancreatic 
cancer (smoking, diabetes, and obesity) are potentially 
modifiable, affording a unique opportunity for preventing 
one of the deadliest cancers. The results of our study can 
be used by policy makers to allocate resources efficiently 
for developing methods for early diagnosis of pancreatic 
cancer, reducing its modifiable risk factors, and 
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evaluating novel treatment strategies to reduce its case-
fatality rate by proper treatment strategies.
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